Log In
BCIQ
Print this Print this
 

Tolcapone (SOM0226)

  Manage Alerts
Collapse Summary General Information
Company SOM Biotech S.L.
DescriptionStabilizer of tetrameric transthyretin (TTR) and TTR fibril disruptor
Molecular Target Transthyretin (TTR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAmyloidosis
Indication DetailsTreat familial amyloid polyneuropathy (FAP); Treat transthyretin (TTR) amyloidosis
Regulatory Designation U.S. - Orphan Drug (Treat transthyretin (TTR) amyloidosis)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/01/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today